Ensign Peak Advisors’s Viridian Therapeutics VRDN Stock Holding History

Ensign Peak Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186K	Buy	10,100 +3,650	+57%	+$58.8K	﹤0.01%	1417
2026 Q1	$126K	Hold	6,450	–	–	﹤0.01%	1506
2025 Q4	$201K	Buy	+6,450	New	+$177K	﹤0.01%	1313
2024 Q1	–	Sell	-89,185	Closed	-$1.94M	–	1752
2023 Q4	$1.94M	Hold	89,185	–	–	﹤0.01%	924
2023 Q3	$1.37M	Hold	89,185	–	–	﹤0.01%	986
2023 Q2	$2.12M	Hold	89,185	–	–	﹤0.01%	856
2023 Q1	$2.27M	Hold	89,185	–	–	﹤0.01%	799
2022 Q4	$2.61M	Sell	89,185 -6,590	-7%	-$152K	0.01%	733
2022 Q3	$1.96M	Buy	95,775 +74,370	+347%	+$1.34M	﹤0.01%	789
2022 Q2	$248K	Hold	21,405	–	–	﹤0.01%	1732
2022 Q1	$396K	Buy	+21,405	New	+$411K	﹤0.01%	1656

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ensign Peak Advisors's VRDN Position: Q2 2026 in Review

Ensign Peak Advisors increased its Viridian Therapeutics (VRDN) stake by 57% in Q2 2026, buying an estimated $58.8K and bringing the position to 10,100 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Ensign Peak Advisors first reported a position in VRDN in Q1 2022 and has held it in 11 quarters since. The position peaked at $2.61M in Q4 2022. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Ensign Peak Advisors held 10,100 shares of Viridian Therapeutics worth $186K as of Q2 2026.
Ensign Peak Advisors bought 3,650 Viridian Therapeutics shares in Q2 2026, an estimated $58.8K.
Viridian Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1417 holding.
Ensign Peak Advisors first reported a position in Viridian Therapeutics in Q1 2022 and has held it in 11 quarters since.
Ensign Peak Advisors's Viridian Therapeutics position peaked at $2.61M in Q4 2022.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.